Development of targeted therapeutic agents for the treatment of FXTAS (2 of 6)

Project: Research project

StatusFinished
Effective start/end date9/30/076/30/12

Funding

  • National Institutes of Health: $792,986.00
  • National Institutes of Health: $793,447.00
  • National Institutes of Health: $860,314.00
  • National Institutes of Health: $74,991.00
  • National Institutes of Health: $787,990.00
  • National Institutes of Health: $798,611.00

Fingerprint

RNA
Small Interfering RNA
Oligonucleotides
Astrocytes
Glutamic Acid
Therapeutics
Antisense DNA
Memantine
Fragile X Syndrome
Poisons
Intellectual Disability
Transgenic Mice
Fragile X Tremor Ataxia Syndrome
Cytoplasm
Alleles
Clinical Trials
Phenotype
Research
Genes

ASJC

  • Medicine(all)